Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep M Gatell

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosineOscar Miró, Sònia López, Marisa Rodríguez de la Concepción, et al.
AIDS Research and Human Retroviruses|December 21, 2010
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adultsElena Ferrer, Luis del Rio, Esteban Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensificationMarta Massanella, Anna Esteve, Maria J Buzón, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|September 2, 2014
Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsAntonio Javier Blasco, Josep M Llibre, Juan Berenguer, et al.
Medicina Clinica|March 3, 2006
[Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients]Laura Gratacòs, Montse Tuset, Carles Codina, et al.
Vaccine|May 26, 2011
A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activitySonsoles Sánchez-Palomino, Marta Massanella, Jorge Carrillo, et al.
Antiviral Therapy|January 25, 2006
In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosisOscar Miró, Joan Villarroya, Glòria Garrabou, et al.
Antiviral Therapy|March 26, 2004
Mitochondrial effects of antiretroviral therapies in asymptomatic patientsSònia López, Oscar Miró, Esteban Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2020
A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected PatientsCsaba Fehér, Montserrat Plana, Alberto Crespo Guardo, et al.
Journal of Virology|June 26, 2015
HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell ResponsesCristina Andrés, Montserrat Plana, Alberto C Guardo, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosineOscar Miró, Sònia López, Marisa Rodríguez de la Concepción, et al.
AIDS Research and Human Retroviruses|December 21, 2010
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adultsElena Ferrer, Luis del Rio, Esteban Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensificationMarta Massanella, Anna Esteve, Maria J Buzón, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|September 2, 2014
Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsAntonio Javier Blasco, Josep M Llibre, Juan Berenguer, et al.
Medicina Clinica|March 3, 2006
[Antiretroviral therapy of HIV infection: duration and reasons for changing the first therapeutic regimen in 518 patients]Laura Gratacòs, Montse Tuset, Carles Codina, et al.
Vaccine|May 26, 2011
A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activitySonsoles Sánchez-Palomino, Marta Massanella, Jorge Carrillo, et al.
Antiviral Therapy|January 25, 2006
In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosisOscar Miró, Joan Villarroya, Glòria Garrabou, et al.
Antiviral Therapy|March 26, 2004
Mitochondrial effects of antiretroviral therapies in asymptomatic patientsSònia López, Oscar Miró, Esteban Martínez, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2020
A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected PatientsCsaba Fehér, Montserrat Plana, Alberto Crespo Guardo, et al.
Journal of Virology|June 26, 2015
HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell ResponsesCristina Andrés, Montserrat Plana, Alberto C Guardo, et al.
Pageof 7